All conditions

Rare Disease

Plain English clinical trial information, updated daily from ClinicalTrials.gov and public government registries. Not medical advice.

146
Trials tracked
4
Recruiting now
25
Australian sites
47
Countries
Country

Showing 146 trials

🇦🇺 AU site

Trial: NCT04969887 — Olivia Newton-John Cancer Research Institute

NCT04969887 · Olivia Newton-John Cancer Research Institute
Active, Not Recruiting Phase 2 Est. completion 1 March 2025
🇦🇺 AU 🇳🇿 NZ

**Who might be able to join this trial:** - You are willing and able to attend scheduled visits, follow the treatment plan, and complete required tests throughout the study. - You have been diagnosed with one of the following cancer types...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT04931342 — Hoffmann-La Roche

NCT04931342 · Hoffmann-La Roche
Active, Not Recruiting Phase 2 Est. completion 28 February 2028
🇦🇺 AU 🇨🇦 CA 🇨🇿 CZ 🇫🇷 FR 🇩🇪 DE

**Who might be able to join this trial:** - You have been diagnosed with a specific type of ovarian, fallopian tube, or peritoneal cancer that has come back or not gone away — including low-grade serous, clear cell, mucinous, carcinosarcom...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT01878617 — St. Jude Children's Research Hospital

NCT01878617 · St. Jude Children's Research Hospital
Active, Not Recruiting Phase 2 Est. completion 13 October 2028
🇦🇺 AU 🇨🇦 CA 🇳🇿 NZ 🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with medulloblastoma (a type of brain tumor) or a closely related type of brain tumor in the back of the brain, confirmed by a pathologist. - You are between 3 and 21 year...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT04261855 — Melanoma and Skin Cancer Trials Limited

NCT04261855 · Melanoma and Skin Cancer Trials Limited
Active, Not Recruiting Phase 2 Est. completion 1 December 2026
🇦🇺 AU

**Who might be able to join this trial:** - You are 18 years of age or older and have agreed in writing to take part in the study. - You have been diagnosed with Merkel cell carcinoma (MCC) that has spread to other parts of the body, confi...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT06254482 — Novartis Pharmaceuticals

NCT06254482 · Novartis Pharmaceuticals
Active, Not Recruiting Phase 2 Est. completion 16 July 2029
🇦🇺 AU 🇦🇹 AT 🇨🇦 CA 🇫🇷 FR 🇩🇪 DE

Who might be able to join this trial: - You have already fully completed the treatment period in a previous related study called PTC518-CNS-002-HD. Who may not be able to join: - You have not completed the full treatment period in the prev...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT04966741 — Rhythm Pharmaceuticals, Inc.

NCT04966741 · Rhythm Pharmaceuticals, Inc.
Completed Phase 3 Est. completion 18 September 2023
🇦🇺 AU 🇪🇸 ES 🇬🇧 GB 🇺🇸 US

**Who might be able to join this trial:** - The child has obesity caused by a specific genetic condition — either a confirmed change in the POMC, PCSK1, or LEPR gene, or a confirmed diagnosis of Bardet-Biedl Syndrome (BBS), shown through g...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT00898079 — Children's Oncology Group

NCT00898079 · Children's Oncology Group
Completed Not Applicable Est. completion 30 June 2018
🇦🇺 AU 🇨🇦 CA 🇳🇿 NZ Puerto Rico 🇨🇭 CH

Who might be able to join this trial: - You have been diagnosed with a primary (original) cancer or have developed a second cancer. - Your cancer diagnosis falls under specific classification codes used in a standard international cancer co...

🇦🇺 AU site

Trial: NCT04157595 — Murdoch Childrens Research Institute

NCT04157595 · Murdoch Childrens Research Institute
Completed Not Applicable Est. completion 31 March 2022
🇦🇺 AU

**Who might be able to join this trial:** - You and your partner are either planning to become pregnant or are in very early pregnancy (less than 10 weeks along at the time of joining, and less than 11 weeks when your sample reaches the lab...

🇦🇺 AU site

Trial: NCT02481817 — Vanderbilt University Medical Center

NCT02481817 · Vanderbilt University Medical Center
Completed Not Applicable Est. completion 10 September 2020
🇦🇺 AU Iceland 🇬🇧 GB 🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - You have a narrowing or abnormality in the lower part of your voice box/upper windpipe (an area called the subglottis) **Who may not be able to join:** - You ar...

🇦🇺 AU site

Trial: NCT04046224 — Sangamo Therapeutics

NCT04046224 · Sangamo Therapeutics
Completed Phase 2 Est. completion 10 April 2025
🇦🇺 AU 🇨🇦 CA 🇩🇪 DE 🇮🇹 IT 🇹🇼 TW

Who might be able to join this trial: - You are 18 years of age or older - You have been officially diagnosed with Fabry disease - You have one or more of the following symptoms: cloudy patches on the surface of the eye (cornea verticillata...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT02923934 — Olivia Newton-John Cancer Research Institute

NCT02923934 · Olivia Newton-John Cancer Research Institute
Completed Phase 2 Est. completion 27 April 2020
🇦🇺 AU

**Who might be able to join this trial:** - You are willing and able to attend scheduled visits, follow the treatment plan, and complete required tests - You have been diagnosed with one of the following cancer types (confirmed by a tissue...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT00514527 — Targanta Therapeutics Corporation

NCT00514527 · Targanta Therapeutics Corporation
Completed Phase 2 Est. completion 1 April 2008
🇦🇺 AU 🇮🇳 IN 🇮🇹 IT 🇷🇴 RO 🇺🇦 UA

Who might be able to join this trial: - You have a serious skin or skin tissue infection that is thought or confirmed to be caused by a type of bacteria called gram-positive bacteria. - You are 18 years old or older, and your body weight is...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT06041906 — Prof. Valérie Mc Lin

NCT06041906 · Prof. Valérie Mc Lin
By Invitation Not Applicable Est. completion 26 October 2026
🇦🇺 AU 🇧🇪 BE 🇨🇦 CA 🇫🇷 FR 🇩🇪 DE

Who might be able to join this trial: - You have been diagnosed with a congenital portosystemic shunt (CPSS), which is an abnormal blood vessel connection present from birth that bypasses the liver (confirm with trial site) Who may not be...

🇦🇺 AU site

Trial: NCT05039866 — Sangamo Therapeutics

NCT05039866 · Sangamo Therapeutics
By Invitation Not Applicable Est. completion 1 March 2029
🇦🇺 AU 🇨🇦 CA 🇩🇪 DE 🇬🇧 GB 🇺🇸 US

Who might be able to join this trial: - You previously received a treatment called ST-920 as part of a separate, related clinical trial - You have agreed and given your consent to take part in this long-term follow-up study Who may not be...

🇦🇺 AU site

Trial: NCT07185997 — ArriVent BioPharma, Inc.

NCT07185997 · ArriVent BioPharma, Inc.
Recruiting Phase 3 Est. completion 1 February 2029
🇦🇺 AU 🇨🇦 CA 🇫🇷 FR 🇬🇷 GR Hong Kong

Who might be able to join this trial: - You have been diagnosed with advanced or spreading non-small cell lung cancer (a common type of lung cancer) that cannot be treated with surgery or radiation to cure it, and this has been confirmed th...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT07039084 — Murdoch Childrens Research Institute

NCT07039084 · Murdoch Childrens Research Institute
Recruiting Not Applicable Est. completion 1 May 2027
🇦🇺 AU

Who might be able to join this trial: - Your child is between 3 and 12 years old at the time of joining the trial - Your child has been diagnosed with a rare genetic disorder - Your child is able to tap on an iPad on their own or by copying...

🇦🇺 AU site

Trial: NCT05589714 — Jaeb Center for Health Research

NCT05589714 · Jaeb Center for Health Research
Recruiting Not Applicable Est. completion 15 December 2029
🇦🇺 AU 🇧🇪 BE 🇧🇷 BR 🇨🇦 CA 🇫🇮 FI

**Who might be able to join this trial:** - You are willing to take part in the study and able to give your consent to participate - You are willing and able to complete all the required visits and assessments at the start of the study - Y...

🇦🇺 AU site

Trial: NCT07070232 — BioNTech SE

NCT07070232 · BioNTech SE
Recruiting Phase 2 Est. completion 1 February 2028
🇦🇺 AU 🇧🇪 BE 🇩🇪 DE 🇮🇹 IT 🇪🇸 ES

**Who might be able to join this trial:** - You must be 18 years of age or older at the time you give your consent to join (or older if required by local law). - Your cancer must have been confirmed by a tissue or cell sample (biopsy) and...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT01920477 — Novartis Pharmaceuticals

NCT01920477 · Novartis Pharmaceuticals
Terminated Phase 3 Est. completion 13 April 2016
🇦🇺 AU 🇬🇷 GR 🇮🇱 IL 🇮🇹 IT 🇯🇵 JP

**Who might be able to join this trial:** - You are between 18 and 70 years old and have been officially diagnosed with Pemphigus Vulgaris (PV) for more than 2 months but less than 10 years. - You have a history of a skin biopsy that confi...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT04612790 — AstraZeneca

NCT04612790 · AstraZeneca
Terminated Phase 3 Est. completion 26 October 2023
🇦🇺 AU 🇧🇬 BG 🇨🇳 CN 🇫🇷 FR 🇩🇪 DE

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with bullous pemphigoid (a blistering skin condition), confirmed through skin biopsy, immune staining of the skin, and a blood test - Yo...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT00958841 — Novartis Pharmaceuticals

NCT00958841 · Novartis Pharmaceuticals
Terminated Phase 2 Est. completion 1 June 2015
🇦🇷 AR 🇦🇺 AU 🇧🇷 BR 🇨🇦 CA 🇫🇷 FR

Who might be able to join this trial: - You must be at least 18 years old (male or female) - You must have a rare type of tumour that comes from hormone-producing tissues, such as tumours of the pancreas, pituitary gland, Nelson syndrome, o...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT03635073 — Takeda

NCT03635073 · Takeda
Terminated Phase 2 Est. completion 30 July 2025
🇦🇺 AU 🇨🇦 CA 🇨🇳 CN 🇮🇱 IL 🇵🇱 PL

**Who might be able to join this trial:** - You must have already taken part in a previous clinical study of soticlestat, and either completed that study fully, or received at least 10 weeks of the study drug in a placebo-controlled study w...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT00004342 — National Center for Research Resources (NCRR)

NCT00004342 · National Center for Research Resources (NCRR)
UNKNOWN Not Applicable
🇦🇺 AU 🇨🇦 CA 🇩🇪 DE 🇬🇧 GB 🇺🇸 US

**Who might be able to join this trial:** - Your blood tests have shown very low levels of infection-fighting white blood cells (called neutrophils) on at least three separate occasions over the past three months. - If cyclic neutropenia i...

🇦🇺 AU site

Trial: NCT03199001 — University College, London

NCT03199001 · University College, London
UNKNOWN Not Applicable Est. completion 19 August 2018
🇦🇺 AU 🇬🇧 GB

**Who might be able to join this trial:** - You have been diagnosed with Fabry Disease confirmed by a genetic test - Both males and females can join - You are at least 9 years old **Who may not be able to join:** - You have a medical reaso...

🇦🇺 AU site

Trial: NCT06560346 — Friedreich's Ataxia Research Alliance

NCT06560346 · Friedreich's Ataxia Research Alliance
Withdrawn Not Applicable Est. completion 1 December 2028
🇦🇺 AU 🇨🇦 CA 🇩🇪 DE 🇮🇹 IT 🇺🇸 US

Who might be able to join this trial: **If you have Friedreich's Ataxia (FA):** - You have been officially diagnosed with Friedreich's Ataxia through genetic testing - You are between 4 and 21 years old when joining the study - You are alr...

Trial: NCT02574728 — Emory University

NCT02574728 · Emory University
Active, Not Recruiting Phase 2 Est. completion 1 June 2026
🇺🇸 US

**Who might be able to join this trial:** - You have a brain tumor (of any grade, except a type called diffuse intrinsic pontine glioma) or a solid tumor outside the brain (including a condition called histiocytosis), and your cancer has c...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT05256290 — Black Diamond Therapeutics, Inc.

NCT05256290 · Black Diamond Therapeutics, Inc.
Active, Not Recruiting Phase 2 Est. completion 3 November 2025
🇺🇸 US

**Who might be able to join this trial:** - Your cancer has been confirmed as non-small cell lung cancer (NSCLC) that is advanced or has spread to other parts of the body, and it has not transformed into a different type called small cell...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT03333616 — Dana-Farber Cancer Institute

NCT03333616 · Dana-Farber Cancer Institute
Active, Not Recruiting Phase 2 Est. completion 30 June 2026
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older at the time you give consent. - You are in reasonably good general health and able to carry out some daily activities (confirm with trial site regarding how this...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT07016282 — Mario Negri Institute for Pharmacological Research

NCT07016282 · Mario Negri Institute for Pharmacological Research
Active, Not Recruiting Not Applicable Est. completion 1 June 2027
🇮🇹 IT 🇸🇪 SE

**Who might be able to join this trial:** - You are a man or woman over 18 years old diagnosed with a condition called ADPKD (a hereditary kidney disease where cysts grow on the kidneys), confirmed using a specific set of medical guidelines...

Trial: NCT06721871 — Napo Pharmaceuticals, Inc.

NCT06721871 · Napo Pharmaceuticals, Inc.
Active, Not Recruiting Phase 3 Est. completion 1 December 2026
🇮🇹 IT 🇦🇪 AE 🇺🇸 US

**Who might be able to join this trial:** - The participant (and/or their parent or guardian) must be willing to sign a consent form agreeing to take part in the study; children older than 7 years old may also need to sign their own agreem...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT05703893 — IRCCS Policlinico S. Donato

NCT05703893 · IRCCS Policlinico S. Donato
Active, Not Recruiting Not Applicable Est. completion 25 October 2024
🇮🇹 IT

Who might be able to join this trial: - You are between 18 and 65 years old and have been diagnosed with a thoracic aortic aneurysm (a bulge in the main blood vessel leaving the heart), either linked to a genetic condition or not - You are...

Trial: NCT01623076 — University of Texas Southwestern Medical Center

NCT01623076 · University of Texas Southwestern Medical Center
Active, Not Recruiting Not Applicable Est. completion 1 June 2030
🇺🇸 US

Who might be able to join this trial: - You must be 6 years old or older - Both males and females can participate - You (or your parent/guardian if you are a child) must be able to give your agreement to take part in the study - If you are...

Trial: NCT00006136 — Boston University

NCT00006136 · Boston University
Completed Phase 2
🇬🇧 GB 🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a type of blood disorder called thalassemia intermedia, with a hemoglobin level of 10 g/dL or lower - You have two specific gene changes (mutations) related to beta th...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT01355913 — Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH

NCT01355913 · Institut fuer anwendungsorientierte Forschung und...
Completed Not Applicable Est. completion 1 October 2016
🇩🇪 DE

Who might be able to join this trial: - You have been diagnosed with myelodysplastic syndrome (MDS), a condition affecting blood cell production in the bone marrow, confirmed through laboratory testing of cells. - You have symptoms or test...

Trial: NCT03384420 — Minovia Therapeutics Ltd.

NCT03384420 · Minovia Therapeutics Ltd.
Completed Phase 2 Est. completion 9 March 2021
🇮🇱 IL

**Who might be able to join this trial:** - You have been diagnosed with Pearson Syndrome, confirmed by a genetic test showing a problem in your mitochondrial DNA (the DNA found in the energy-producing parts of your cells). - Your mother's...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT01744782 — Amgen

NCT01744782 · Amgen
Completed Phase 3 Est. completion 13 December 2016
🇧🇷 BR 🇺🇸 US

**Who might be able to join this trial:** - You have been officially diagnosed with cystinosis. - Your liver function test results have been stable (not significantly raised) in the 6 months before the screening appointment. - Your kidney...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
Completed Phase 2
🇺🇸 US

**Who might be able to join this trial:** - Your newborn has high levels of bilirubin (a yellow pigment in the blood) in their blood - The high bilirubin is caused by a blood type mismatch between mother and baby (ABO hemolytic disease), co...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00004324 — National Center for Research Resources (NCRR)

NCT00004324 · National Center for Research Resources (NCRR)
Completed Not Applicable
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with Obsessive Compulsive Disorder (OCD) or Tourette Syndrome, confirmed using standard medical diagnostic guidelines (DSM-IV criteria) Who may not be able to join: - There ar...

Trial: NCT03680365 — Jett Foundation, Inc.

NCT03680365 · Jett Foundation, Inc.
Completed Not Applicable Est. completion 15 March 2019
🇺🇸 US

**Who might be able to join this trial:** - You are either a person with Duchenne Muscular Dystrophy (DMD) who is 11 years old or older, OR a parent or legal guardian of a child under 18 who has DMD - You have an official written diagnosis...

Trial: NCT00004412 — Susan P. Perrine

NCT00004412 · Susan P. Perrine
Completed Phase 2 Est. completion 1 December 2002
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with a significant sickle cell condition, including Hemoglobin SS, Hemoglobin S-beta thalassemia, or a related hemoglobin variant - You are between 16 and 60 years old - You ha...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT02748044 — Sun Yat-sen University

NCT02748044 · Sun Yat-sen University
Completed Not Applicable Est. completion 1 April 2016
🇨🇳 CN

Who might be able to join this trial: - You have had an eye examination at one of the hospitals working with this trial, and your eye health information was recorded there. Who may not be able to join: - No specific exclusion criteria have...

Trial: NCT03290469 — Illumina, Inc.

NCT03290469 · Illumina, Inc.
Completed Not Applicable Est. completion 30 April 2019
🇺🇸 US

**Who might be able to join this trial:** - The baby is currently admitted to a Neonatal Intensive Care Unit (NICU) or Intensive Care Unit (ICU) at a participating hospital, and is between 0 and 120 days old at the time of joining the stud...

Trial: NCT02365922 — University of California, San Francisco

NCT02365922 · University of California, San Francisco
Completed Not Applicable Est. completion 1 August 2020
🇨🇦 CA 🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with one of the following conditions: behavioral variant frontotemporal dementia (bvFTD), primary progressive aphasia (PPA), semantic variant PPA, nonfluent variant PPA, f...

Trial: NCT00004786 — National Center for Research Resources (NCRR)

NCT00004786 · National Center for Research Resources (NCRR)
Completed Phase 3

**Who might be able to join this trial:** - You have been diagnosed with Raynaud's phenomenon (a condition causing reduced blood flow to the fingers/toes) that is caused by systemic sclerosis (a connective tissue disease), confirmed using s...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00004843 — National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NCT00004843 · National Institute of Diabetes and Digestive and K...
Completed Not Applicable Est. completion 30 March 1999

**Who might be able to join this trial:** - You have been diagnosed with a mild, symptom-free form of overactive parathyroid glands (confirmed by tissue testing) - Your blood calcium levels have been slightly elevated (in a specific range)...

Trial: NCT05684523 — Max Zeller Soehne AG

NCT05684523 · Max Zeller Soehne AG
Completed Phase 4 Est. completion 20 December 2023
🇨🇭 CH

Who might be able to join this trial: - You are generally healthy - You can be male or female - You are between 18 and 65 years old - You have occasional sleep problems on average 1 to 2 nights per week, with a sleep quality score above 5 o...

Phase 4: Approved of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00004330 — National Center for Research Resources (NCRR)

NCT00004330 · National Center for Research Resources (NCRR)
Completed Not Applicable
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with one of these types of acute porphyria: Acute Intermittent Porphyria, Hereditary Coproporphyria, or Variegate Porphyria - Your porphyria attacks happen in a clear cycle...

Trial: NCT00006130 — UCSF Benioff Children's Hospital Oakland

NCT00006130 · UCSF Benioff Children's Hospital Oakland
Completed Not Applicable
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with stage I, II, or III avascular necrosis (a condition where bone tissue dies due to lack of blood supply) in the hip, confirmed by an MRI or X-ray - Your avascular necro...

Trial: NCT03954652 — University Hospital Tuebingen

NCT03954652 · University Hospital Tuebingen
Completed Not Applicable Est. completion 1 October 2022
🇩🇪 DE

Who might be able to join this trial: - Your condition does not yet have a clear genetic explanation identified - There is reason to believe your condition may be caused by a genetic (inherited) factor - Healthy parents of an affected perso...

Trial: NCT05245123 — Universitätsklinikum Hamburg-Eppendorf

NCT05245123 · Universitätsklinikum Hamburg-Eppendorf
Completed Not Applicable Est. completion 31 March 2023
🇩🇪 DE

**Who might be able to join this trial:** *For families affected by a rare disease:* - Your family includes at least one child aged 0 to 17 years who has been diagnosed with a rare solid tumour in the abdomen - You and your child agree to...

Trial: NCT00004284 — National Center for Research Resources (NCRR)

NCT00004284 · National Center for Research Resources (NCRR)
Completed Phase 3

**Who might be able to join this trial:** - You have been diagnosed with a condition called "absorptive hypercalciuria," meaning your intestines absorb too much calcium from food - Tests show your body releases an unusually high amount of...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00004784 — National Center for Research Resources (NCRR)

NCT00004784 · National Center for Research Resources (NCRR)
Completed Phase 3

**Who might be able to join this trial:** - You have been diagnosed with primary biliary cirrhosis (a liver condition), with symptoms lasting at least 6 months before joining the study - A liver biopsy taken within the last 6 months is con...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00004811 — National Center for Research Resources (NCRR)

NCT00004811 · National Center for Research Resources (NCRR)
Completed Phase 2

**Who might be able to join this trial:** - You have a confirmed fungal infection (proven by a lab culture), specifically chronic cavitary histoplasmosis, histoplasmosis that has spread outside the lungs (such as affecting mucous membranes)...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT04200664 — University College, London

NCT04200664 · University College, London
Completed Not Applicable Est. completion 19 October 2021
🇬🇧 GB

**Who might be able to join this trial:** - **Siderosis group:** Adults aged 18 or older (male or female) who have been diagnosed with a condition called idiopathic superficial siderosis (iSS) — a specific neurological condition — confirme...

Trial: NCT06009185 — Bial - Portela C S.A.

NCT06009185 · Bial - Portela C S.A.
Completed Phase 2 Est. completion 17 February 2022
🇦🇹 AT 🇩🇪 DE 🇮🇹 IT 🇵🇹 PT 🇪🇸 ES

**Who might be able to join this trial:** - You must have completed a specific visit (called "MPV3") in the earlier related study called BIA-51058-201. - You must be able to understand and be willing to sign a consent form agreeing to take...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00007059 — National Center for Research Resources (NCRR)

NCT00007059 · National Center for Research Resources (NCRR)
Completed Not Applicable
🇺🇸 US

**Who might be able to join this trial:** - You have received a liver or kidney transplant (placed in the normal position in the body) and started taking a medication called mycophenolate mofetil (as part of your anti-rejection medication p...

Trial: NCT06508398 — Danylo Halytsky Lviv National Medical University

NCT06508398 · Danylo Halytsky Lviv National Medical University
Completed Not Applicable Est. completion 30 June 2019
🇺🇦 UA

Who might be able to join this trial: - You are currently staying in an Intensive Care Unit (ICU) in a hospital. - You have been diagnosed with an infection that was caught as a result of receiving medical care (sometimes called a hospital-...

Trial: NCT05211648 — Aktiia SA

NCT05211648 · Aktiia SA
Completed Not Applicable Est. completion 23 May 2023
🇺🇸 US

Who might be able to join this trial: - You are fluent in English, both reading and speaking - You are already enrolled in the Remote Hypertension Program - Your blood pressure readings have been above 140/90 on average across your last 3 c...

Trial: NCT06225141 — Imagine Institute

NCT06225141 · Imagine Institute
Completed Not Applicable Est. completion 2 January 2024
🇫🇷 FR

**Who might be able to join this trial:** - You are attending a medical genetics, jaw surgery, or craniofacial (skull and face) surgery appointment as part of care for a rare disease (in France, a condition affecting fewer than 30,000 peop...

Trial: NCT04057703 — University Hospital, Bordeaux

NCT04057703 · University Hospital, Bordeaux
Completed Not Applicable Est. completion 4 December 2016

**Who might be able to join this trial:** - You have been diagnosed with Chronic Immune Thrombocytopenic Purpura (a condition where the immune system attacks platelets), Autoimmune Hemolytic Anemia (a condition where the immune system attac...

Trial: NCT04564274 — National Heart, Lung, and Blood Institute (NHLBI)

NCT04564274 · National Heart, Lung, and Blood Institute (NHLBI)
Completed Not Applicable Est. completion 20 May 2022
🇺🇸 US

Who might be able to join this trial: - The person being reported on must be at least 1 month old - The person filling out the report must have access to the internet and be able to read and answer questions in English or Spanish Who may n...

Trial: NCT00004335 — National Center for Research Resources (NCRR)

NCT00004335 · National Center for Research Resources (NCRR)
Completed Not Applicable
🇺🇸 US

**Who might be able to join this trial:** - Children aged 7 to 16 who are suspected or confirmed to have a problem with the glands that control growth and puberty (the hypothalamus, pituitary gland, or reproductive glands) - Children with...

Trial: NCT06466109 — National Yang Ming Chiao Tung University

NCT06466109 · National Yang Ming Chiao Tung University
Completed Not Applicable Est. completion 27 August 2025
🇹🇼 TW

Who might be able to join this trial: **For patients:** - You are between 8 and 19 years old. - You have been diagnosed with a rare disease. - You are able to communicate in Chinese. **For parents:** - You are the mother or father of a ch...

Trial: NCT06480968 — Connecta Therapeutics, S.L.

NCT06480968 · Connecta Therapeutics, S.L.
Completed Phase 1 Est. completion 11 November 2024
🇪🇸 ES

**Who might be able to join this trial:** - You are a healthy male, or a healthy female who cannot become pregnant (either due to surgical sterilisation such as a hysterectomy or tubal ligation, or because you have gone through menopause)....

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00140881 — Organon and Co

NCT00140881 · Organon and Co
Completed Phase 4 Est. completion 14 February 2003

Who might be able to join this trial: - Children (boys or girls) between the ages of 2 and 14 who have infrequent, occasional episodes of asthma. Who may not be able to join: - No specific exclusion criteria were listed in the provided inf...

Phase 4: Approved of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00004688 — Emory University

NCT00004688 · Emory University
Completed Phase 2

**Who might be able to join this trial:** - You have a brain tumor that has been confirmed by a tissue sample (biopsy) and it has come back or stopped responding to treatment — specific types include glioblastoma multiforme, anaplastic astr...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT05161494 — Universiteit Antwerpen

NCT05161494 · Universiteit Antwerpen
Completed Not Applicable Est. completion 1 July 2025
🇧🇪 BE

Who might be able to join this trial: - You have been diagnosed with a condition called Tuberous Sclerosis Complex (TSC), confirmed using specific medical guidelines from 2012 - You are 6 years old or older - You are able to walk at least 6...

Trial: NCT05961267 — University Hospital, Bordeaux

NCT05961267 · University Hospital, Bordeaux
Completed Not Applicable Est. completion 28 June 2024
🇫🇷 FR

**Who might be able to join this trial:** - You are a woman aged 18 or older - You have not yet gone through menopause (this applies only to a specific subgroup within the trial related to contraception use) - You have been diagnosed with o...

Trial: NCT00004397 — National Center for Research Resources (NCRR)

NCT00004397 · National Center for Research Resources (NCRR)
Completed Phase 1

**Who might be able to join this trial:** - You have been diagnosed with acute intermittent porphyria, variegate porphyria, or hereditary coproporphyria - Your condition causes 6 or more attacks (flare-ups) per year - If you are already rec...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00004980 — Yale University

NCT00004980 · Yale University
Completed Phase 2 Est. completion 1 January 2005
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with schizophrenia or schizoaffective disorder, confirmed through a structured clinical interview. - You hear voices (spoken speech) at least 5 times per day and can make out w...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT01235624 — University Hospital, Montpellier

NCT01235624 · University Hospital, Montpellier
Completed Not Applicable Est. completion 1 April 2013
🇫🇷 FR

Who might be able to join this trial: - You have been diagnosed with a condition called retinitis pigmentosa (an eye disease that causes gradual vision loss) - Your retinitis pigmentosa has been confirmed to be passed down through families...

Trial: NCT06714370 — Ono Pharmaceutical Co., Ltd.

NCT06714370 · Ono Pharmaceutical Co., Ltd.
Completed Not Applicable Est. completion 31 March 2026
🇹🇼 TW

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with primary central nervous system lymphoma (a type of cancer affecting the brain or spinal cord) that has come back or stopped respondi...

Trial: NCT00004800 — National Institute of Allergy and Infectious Diseases (NIAID)

NCT00004800 · National Institute of Allergy and Infectious Disea...
Completed Phase 3

**Who might be able to join this trial:** - Newborns being enrolled at their first vaccine clinic visit - Baby girls who weigh between 3.2 and 3.8 kg at their first vaccination - Baby boys who weigh between 3.4 and 4.0 kg at their first vac...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00004802 — National Center for Research Resources (NCRR)

NCT00004802 · National Center for Research Resources (NCRR)
Completed Phase 3

**Who might be able to join this trial:** - You have been diagnosed with hypokalemic periodic paralysis (a condition where low potassium causes episodes of muscle weakness), with typical symptoms and normal thyroid hormone levels - You or a...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00004467 — National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NCT00004467 · National Institute of Diabetes and Digestive and K...
Completed Phase 3 Est. completion 1 November 2006
🇺🇸 US

**Who might be able to join this trial:** - You are between 18 and 70 years old - You have been diagnosed with sudden (acute) liver failure, meaning your liver stopped working properly within the last 26 weeks and you have no history of lo...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT05070988 — Assistance Publique - Hôpitaux de Paris

NCT05070988 · Assistance Publique - Hôpitaux de Paris
Completed Not Applicable Est. completion 29 November 2021
🇫🇷 FR

**Who might be able to join this trial:** - You are at least 6 years old (children and adults are both welcome) - You have been diagnosed with a rare disease and are being cared for at the Necker Enfants Malades Hospital in Paris - Your rar...

Trial: NCT05612139 — Orthofix s.r.l.

NCT05612139 · Orthofix s.r.l.
Completed Not Applicable Est. completion 20 February 2025
🇫🇷 FR

**Who might be able to join this trial:** - You are a child or teenager older than 18 months and younger than 18 years old at the time of surgery - Your bones are still growing (you have not reached full skeletal maturity) - You have been d...

Trial: NCT00004694 — University of Iowa

NCT00004694 · University of Iowa
Completed Not Applicable

**Who might be able to join this trial:** - You have been diagnosed with hereditary angioedema (HAE), confirmed through specific blood tests (C4 and C1 inhibitor levels) and/or a family history of the condition - You have Type I or Type II...

Trial: NCT00004437 — FDA Office of Orphan Products Development

NCT00004437 · FDA Office of Orphan Products Development
Completed Phase 2

Who might be able to join this trial: - You have been diagnosed with neurofibromatosis type 2 (a condition that causes tumors to grow on nerves related to hearing and balance) - You are scheduled to have a tumor removed (either your first t...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT02116764 — National Institute of Allergy and Infectious Diseases (NIAID)

NCT02116764 · National Institute of Allergy and Infectious Disea...
Completed Not Applicable Est. completion 2 June 2022
🇺🇸 US

Who might be able to join this trial: - You must be older than 2 years of age. - You must already be enrolled in and receiving treatment under a Chronic Granulomatous Disease (CGD) program at the NIAID (a government health research institut...

Trial: NCT00171301 — Novartis Pharmaceuticals

NCT00171301 · Novartis Pharmaceuticals
Completed Phase 4 Est. completion 1 May 2008
🇪🇬 EG 🇱🇧 LB Oman 🇸🇦 SA Syria

**Who might be able to join this trial:** - You must have already completed the full 12-month main study (NCT00171171). - Female patients who have had their first period and are sexually active must be using an effective form of birth contr...

Phase 4: Approved of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00014729 — University of North Carolina

NCT00014729 · University of North Carolina
Completed Phase 1

"Who might be able to join this trial: - You have been diagnosed with recessive dystrophic epidermolysis bullosa (RDEB), either the Hallopeau-Siemens type or the non-Hallopeau-Siemens type - You are already enrolled in the National Epidermo...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT01894165 — Origin Biosciences

NCT01894165 · Origin Biosciences
Completed Phase 1 Est. completion 1 September 2013
🇺🇸 US

Who might be able to join this trial: - You are between 18 and 60 years old and weigh between 55 kg (about 121 lbs) and 100 kg (about 220 lbs) - You are willing and able to sign a written consent form agreeing to take part - If you are a wo...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00004809 — National Center for Research Resources (NCRR)

NCT00004809 · National Center for Research Resources (NCRR)
Completed Phase 1

**Who might be able to join this trial:** - You have been diagnosed with homozygous familial hypercholesterolemia (a rare inherited condition causing very high cholesterol) - Your LDL ("bad") cholesterol level is above 500 mg/dL - The cond...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00498420 — Zymenex A/S

NCT00498420 · Zymenex A/S
Completed Not Applicable Est. completion 1 September 2009
🇨🇿 CZ 🇩🇪 DE 🇳🇴 NO 🇬🇧 GB

Who might be able to join this trial: - You (or your legal guardian) must be willing and able to sign a consent form before taking part in any study activities. - You must have a confirmed diagnosis of Alpha Mannosidosis, with visible signs...

Trial: NCT00303329 — Novartis Pharmaceuticals

NCT00303329 · Novartis Pharmaceuticals
Completed Phase 2 Est. completion 1 October 2008
🇧🇪 BE 🇨🇦 CA 🇫🇷 FR 🇩🇪 DE 🇮🇹 IT

Who might be able to join this trial: - You must have already completed the full 12-month main part of this study. - Female patients who have started their periods and are sexually active must be using two forms of contraception (such as tw...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT07428941 — AI Labs Group S.L

NCT07428941 · AI Labs Group S.L
Completed Not Applicable Est. completion 13 September 2024
🇪🇸 ES

Who might be able to join this trial: - Primary care doctors who are fully qualified and certified in their field, regardless of how many years they have been practicing. - Cases involving clear, high-quality photos of patients who have var...

Trial: NCT00004496 — University of Texas

NCT00004496 · University of Texas
Completed Phase 1
🇺🇸 US

**Who might be able to join this trial:** - (Group 1) People who are currently on regular, long-term dialysis (hemodialysis) - (Group 2) People who have recently received a kidney transplant from a deceased donor and are at high risk of su...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT03434418 — Duke University

NCT03434418 · Duke University
Completed Phase 2 Est. completion 12 October 2022
🇺🇸 US

**Who might be able to join this trial:** - Your lung cancer tumor has been tested in a certified lab and found to have one of these specific genetic changes: EGFR exon 18 G719X, exon 20 S768I, or exon 21 L861Q (having more than one mutati...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00004478 — Icahn School of Medicine at Mount Sinai

NCT00004478 · Icahn School of Medicine at Mount Sinai
Completed Not Applicable Est. completion 1 March 2006
🇺🇸 US

"Who might be able to join this trial: - You have low blood pressure when standing up (called orthostatic hypotension), meaning your systolic blood pressure drops by at least 20 points and your diastolic blood pressure drops by at least 15...

Trial: NCT00004654 — National Center for Research Resources (NCRR)

NCT00004654 · National Center for Research Resources (NCRR)
Completed Phase 3

**Who might be able to join this trial:** - You have been diagnosed with Hereditary Hemorrhagic Telangiectasia (HHT), a condition affecting blood vessels, AND have at least 2 of the following: a close family member (parent, sibling, or chil...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00004441 — Children's Hospital Medical Center, Cincinnati

NCT00004441 · Children's Hospital Medical Center, Cincinnati
Completed Not Applicable
🇮🇹 IT 🇺🇸 US

**Who might be able to join this trial:** - You have cystic fibrosis and liver disease, shown by at least one of the following: liver enzyme levels that were significantly higher than normal at least once in the past year; a noticeably enla...

Trial: NCT00006058 — National Center for Research Resources (NCRR)

NCT00006058 · National Center for Research Resources (NCRR)
Completed Not Applicable
🇺🇸 US

Who might be able to join this trial: - Premature babies born before 33 weeks of pregnancy who need a breathing machine (ventilator) to help them breathe - Babies born at or after 33 weeks of pregnancy who have severe breathing problems, ne...

Trial: NCT00004414 — University of Michigan

NCT00004414 · University of Michigan
Completed Not Applicable
🇺🇸 US

Who might be able to join this trial: - Newborns weighing less than 1,000 grams (about 2.2 pounds) at birth AND born at 28 weeks of pregnancy or earlier, who need more than half of their nutrition given through a vein within the first 7 day...

Trial: NCT02505308 — Royal Devon and Exeter NHS Foundation Trust

NCT02505308 · Royal Devon and Exeter NHS Foundation Trust
Completed Not Applicable Est. completion 31 March 2019
🇬🇧 GB

**Who might be able to join this trial:** - You are between 16 and 75 years old (inclusive) - Your background reflects the mix of people who live in the local area - You are able to understand the trial information and give your own consent...

Trial: NCT00005103 — National Center for Research Resources (NCRR)

NCT00005103 · National Center for Research Resources (NCRR)
Completed Not Applicable
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with a well-documented case of porphyria cutanea tarda (PCT), either the sporadic type (Type I) or the familial type (Type II) - Your blood tests show higher than normal levels...

Trial: NCT02230566 — Ultragenyx Pharmaceutical Inc

NCT02230566 · Ultragenyx Pharmaceutical Inc
Completed Phase 3 Est. completion 1 May 2016
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with MPS 7 (Mucopolysaccharidosis type 7), confirmed through a blood, skin cell, or genetic test. - Your urine test shows a certain waste product (called glycosaminoglycan...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT03565822 — University Hospital, Lille

NCT03565822 · University Hospital, Lille
Completed Not Applicable Est. completion 15 July 2019
🇫🇷 FR

**Who might be able to join this trial:** - You are the parent of a child who is between 12 and 36 months old and had surgery as a newborn for one of the following conditions: oesophageal atresia (a problem with the food pipe), congenital d...

Trial: NCT00004416 — University of Texas

NCT00004416 · University of Texas
Completed Not Applicable

**Who might be able to join this trial:** - You have been diagnosed with achalasia (a condition affecting swallowing) confirmed by specific tests measuring muscle activity in the esophagus and a camera examination of the throat/stomach - Yo...

Trial: NCT00004795 — National Center for Research Resources (NCRR)

NCT00004795 · National Center for Research Resources (NCRR)
Completed Phase 3

**Who might be able to join this trial:** - You have been diagnosed with systemic lupus erythematosus (lupus) based on recognised medical guidelines - Your lupus is considered mild to moderate in severity - You are taking prednisone (or a s...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00004494 — Stony Brook University

NCT00004494 · Stony Brook University
Completed Phase 1
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with adult respiratory distress syndrome (ARDS) along with sepsis (a serious body-wide response to infection). - Your ARDS involves low oxygen levels that do not improve with e...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00004396 — National Center for Research Resources (NCRR)

NCT00004396 · National Center for Research Resources (NCRR)
Completed Phase 2
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with acute intermittent porphyria (a rare genetic condition affecting the body's ability to produce a substance called heme) and your condition has been in remission for at lea...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00004339 — National Center for Research Resources (NCRR)

NCT00004339 · National Center for Research Resources (NCRR)
Completed Phase 3
🇺🇸 US

"Who might be able to join this trial: - You have been diagnosed with Wilson disease and are experiencing neurological symptoms (such as movement or coordination problems) or psychiatric symptoms (such as mood or behavioral changes) - You h...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00004409 — State University of New York

NCT00004409 · State University of New York
Completed Phase 2
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with Dupuytren's disease that has left one or more fingers bent/curled and unable to straighten by at least 20–30 degrees - A doctor can feel a tight cord-like band under...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT02706639 — National Heart, Lung, and Blood Institute (NHLBI)

NCT02706639 · National Heart, Lung, and Blood Institute (NHLBI)
Completed Not Applicable Est. completion 7 March 2025
🇺🇸 US

**Who might be able to join this trial:** - You are between 0 and 85 years old and have a diagnosis (confirmed or suspected) of Williams Syndrome (WS), including typical or unusual forms diagnosed by a knowledgeable doctor - You are betwee...

Trial: NCT01784679 — Ultragenyx Pharmaceutical Inc

NCT01784679 · Ultragenyx Pharmaceutical Inc
Completed Not Applicable Est. completion 30 November 2017
🇧🇬 BG 🇨🇦 CA 🇫🇷 FR 🇬🇧 GB 🇺🇸 US

**Who might be able to join this trial:** - You must be willing and able to give electronic consent for your medical information to be shared with the study organizers. - You must have been diagnosed with one of the following conditions: G...

Trial: NCT05908656 — Sanofi

NCT05908656 · Sanofi
Completed Not Applicable Est. completion 26 August 2024
🇺🇸 US

**Who might be able to join this trial:** - (Phase 1 – Data Review): Anyone whose medical records are held within one of the participating healthcare systems may be included in this first stage. - (Phase 2 – Identifying Candidates): People...

Trial: NCT07573072 — Istituto Ortopedico Rizzoli

NCT07573072 · Istituto Ortopedico Rizzoli
Completed Not Applicable Est. completion 22 July 2025
🇮🇹 IT

Who might be able to join this trial: - You must be a patient who has a biological sample (such as tissue or blood) stored in a biobank that is part of the CRB IOR collection. - You must have been diagnosed with one of the following conditi...

Trial: NCT01380054 — University Hospital, Montpellier

NCT01380054 · University Hospital, Montpellier
Completed Not Applicable Est. completion 20 May 2016
🇫🇷 FR

**Who might be able to join this trial:** - You have been diagnosed with pulmonary arterial hypertension (a condition affecting blood pressure in the lungs) - Your condition has been stable for at least 3 months - Your condition falls into...

Trial: NCT00010374 — Synapse Biomedical

NCT00010374 · Synapse Biomedical
Completed Not Applicable Est. completion 1 October 2008
🇨🇦 CA 🇺🇸 US

Who might be able to join this trial: - You must be 18 years old or older - You must have a spinal cord injury in the neck area and depend on a machine to help you breathe - Your condition must be medically stable after the spinal cord inju...

Trial: NCT03748966 — Massachusetts General Hospital

NCT03748966 · Massachusetts General Hospital
Completed Early Phase 1 Est. completion 1 March 2025
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with XLH (X-linked hypophosphatemia), confirmed either by a family history where no father passed it to a son, or by a genetic test showing a PHEX gene mutation - Your para...

Early Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00004690 — Cellegy Pharmaceuticals

NCT00004690 · Cellegy Pharmaceuticals
Completed Phase 3

**Who might be able to join this trial:** - You have been diagnosed with nonbullous congenital ichthyosiform erythroderma (NBCIE), a skin condition present from birth that causes widespread redness, scaling, and thickening of the skin acro...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT01048892 — Children's Oncology Group

NCT01048892 · Children's Oncology Group
Completed Phase 1 Est. completion 1 June 2013
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with one of these cancers (confirmed by a tissue test): neuroblastoma, rhabdomyosarcoma, Wilms tumor, retinoblastoma, adrenocortical carcinoma, or carcinoid tumor - Your cancer...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT04844697 — Istituto Ortopedico Rizzoli

NCT04844697 · Istituto Ortopedico Rizzoli
Completed Not Applicable Est. completion 31 December 2022
🇮🇹 IT

Who might be able to join this trial: - You have been diagnosed with Multiple Osteochondromas (a condition where multiple bony growths form near the joints), either through medical examination or genetic testing - You have been diagnosed wi...

Trial: NCT00016458 — Fred Hutchinson Cancer Center

NCT00016458 · Fred Hutchinson Cancer Center
Completed Phase 2
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with diffuse systemic sclerosis (a serious form of scleroderma that affects the whole body) - Your disease is getting worse, with a skin score of at least 16 (a measure of...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT01880983 — University of Alabama at Birmingham

NCT01880983 · University of Alabama at Birmingham
Completed Not Applicable Est. completion 31 December 2020
🇺🇸 US

Who might be able to join this trial: - You must already be enrolled in a separate study called the Longitudinal Study of the Porphyrias and have a diagnosis of EPP (Erythropoietic Protoporphyria). - You, or your parent or guardian if you a...

Trial: NCT05581550 — National Cancer Centre, Singapore

NCT05581550 · National Cancer Centre, Singapore
Completed Not Applicable Est. completion 17 July 2025
🇸🇬 SG

Who might be able to join this trial: - You have been diagnosed with nasopharyngeal cancer (cancer at the back of the nose/throat) that is advanced, has spread, or has come back, and you are already scheduled to have an FDG PET scan as part...

Trial: NCT00004325 — National Center for Research Resources (NCRR)

NCT00004325 · National Center for Research Resources (NCRR)
Completed Not Applicable
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed (at some point in your life) with at least one of the following: Tourette syndrome, obsessive compulsive disorder (OCD), or chronic tics - Teenagers who are severely affected b...

Trial: NCT07051213 — Universitaire Ziekenhuizen KU Leuven

NCT07051213 · Universitaire Ziekenhuizen KU Leuven
Completed Not Applicable Est. completion 5 July 2024
🇧🇪 BE

Who might be able to join this trial: - You have a moderate to profound intellectual disability or developmental delay - You have a mild to moderate intellectual disability or developmental delay, AND more than one family member is affected...

Trial: NCT03650569 — FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS

NCT03650569 · FROM- Fondazione per la Ricerca Ospedale di Bergam...
Completed Not Applicable Est. completion 16 February 2021
🇮🇹 IT

**Who might be able to join this trial:** - You have been diagnosed with Angelman syndrome through genetic/molecular testing. **Who may not be able to join:** - You do not meet the accepted diagnostic criteria for Angelman syndrome. - You...

Trial: NCT00004305 — National Center for Research Resources (NCRR)

NCT00004305 · National Center for Research Resources (NCRR)
Completed Not Applicable
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with a kidney condition called IgA glomerulonephritis, which is a type of kidney disease caused by a build-up of a protein (IgA) in the kidneys Who may not be able to join: -...

Trial: NCT00004685 — Ohio State University

NCT00004685 · Ohio State University
Completed Not Applicable

**Who might be able to join this trial:** - You have been diagnosed with facioscapulohumeral muscular dystrophy (a specific type of muscle disease affecting the face, shoulders, and limbs) - You have weakness in the muscles of your face, su...

Trial: NCT06568055 — Takeda

NCT06568055 · Takeda
Completed Not Applicable Est. completion 31 October 2025
🇬🇧 GB

**Who might be able to join this trial:** *For the main group (people whose CMV did not respond to treatment):* - You are 18 years old or older - You received a kidney transplant on or after June 2016 - You had a CMV infection (virus in th...

Trial: NCT03679598 — University of Alabama at Birmingham

NCT03679598 · University of Alabama at Birmingham
Completed Phase 2 Est. completion 30 November 2023
🇺🇸 US

**Who might be able to join this trial:** - You are between 18 and 80 years old - You have a confirmed diagnosis of Alpha-1 Antitrypsin Deficiency (AATD) with a specific genetic type known to cause low or poorly functioning AAT protein (su...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT05643274 — Nantes University Hospital

NCT05643274 · Nantes University Hospital
Completed Not Applicable Est. completion 8 March 2023
🇫🇷 FR

**Who might be able to join this trial:** - You are a child or adult who has been identified as having developmental or neurological difficulties, and doctors strongly suspect you have a rare genetic condition (either running in the family...

Trial: NCT00016445 — University of Utah

NCT00016445 · University of Utah
Completed Phase 2 Est. completion 1 August 2007
🇺🇸 US

Who might be able to join this trial: - The patient must have cystic fibrosis and not yet have gone through puberty - The patient must be able to perform breathing tests (lung function tests) - The patient must be significantly below the no...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT01304043 — ARCAGY/ GINECO GROUP

NCT01304043 · ARCAGY/ GINECO GROUP
Completed Not Applicable
🇫🇷 FR

**Who might be able to join this trial:** - You must be over 18 years old - You must have been diagnosed with a specific type of ovarian tumour (affecting the cells that produce eggs or hormones), confirmed by a tissue sample test - You may...

Trial: NCT00004474 — Roswell Park Cancer Institute

NCT00004474 · Roswell Park Cancer Institute
Completed Phase 3 Est. completion 1 August 2007
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with severe aplastic anemia (a condition where the bone marrow stops making enough blood cells) - Your bone marrow biopsy shows very low activity, with less than 20% of no...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT02670694 — Baylor College of Medicine

NCT02670694 · Baylor College of Medicine
Completed Not Applicable Est. completion 1 July 2013
🇺🇸 US

Who might be able to join this trial: - Your child must be registered in the Rare Diseases Clinical Research Network (RDCRN) registry for Angelman syndrome (AS), Rett syndrome (RTT), or Prader-Willi syndrome (PWS) (confirm with trial site)....

Trial: NCT00004665 — National Center for Research Resources (NCRR)

NCT00004665 · National Center for Research Resources (NCRR)
Completed Phase 2

**Who might be able to join this trial:** - You have been diagnosed with systemic lupus erythematosus (lupus) based on recognised medical criteria - Your lupus is considered mild to moderate - You are currently taking prednisone (or a simi...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT01170559 — Barts & The London NHS Trust

NCT01170559 · Barts & The London NHS Trust
Completed Not Applicable Est. completion 1 August 2016
🇬🇧 GB

**Who might be able to join this trial:** - You are 18 years of age or older - You have a clear history of episodes where your heart suddenly starts beating very fast, with a clear start and stop, and these may come with shortness of breath...

Trial: NCT00004398 — National Center for Research Resources (NCRR)

NCT00004398 · National Center for Research Resources (NCRR)
Completed Phase 1

**Who might be able to join this trial:** - You have been diagnosed with acute intermittent porphyria, variegate porphyria, or hereditary coproporphyria - Your symptoms are recent and have not been present for longer than 2 weeks - It has b...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT03012620 — UNICANCER

NCT03012620 · UNICANCER
Completed Phase 2 Est. completion 26 December 2022
🇫🇷 FR

**Who might be able to join this trial:** - You have signed a consent form agreeing to take part in the study. - You have been diagnosed (confirmed by tissue testing) with one of the specific rare cancers covered by this trial, which inclu...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00004286 — National Center for Research Resources (NCRR)

NCT00004286 · National Center for Research Resources (NCRR)
Completed Phase 3

**Who might be able to join this trial:** - You have been diagnosed with a condition called chronic inflammatory demyelinating polyneuropathy (CIDP), which is a nerve disease that causes inflammation and damage to the protective covering ar...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00004376 — National Center for Research Resources (NCRR)

NCT00004376 · National Center for Research Resources (NCRR)
Completed Phase 3

**Who might be able to join this trial:** - You have been diagnosed with Tourette syndrome or another long-term tic disorder, based on standard medical guidelines (DSM-IV) - You have also been diagnosed with Attention Deficit Hyperactivity...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00004658 — National Center for Research Resources (NCRR)

NCT00004658 · National Center for Research Resources (NCRR)
Completed Phase 2

Who might be able to join this trial: - You have a complex condition where certain skin cells show too much activity of a specific enzyme called 5'-nucleotidase (confirm with trial site) - You experience repeated or frequent infections - Yo...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)